Acurx Pharmaceuticals, Inc. SEC filings ACXP
Acurx Pharmaceuticals, Inc. has 245 filings in SEC EDGAR's recent list, going back to Apr 3, 2018. Its latest annual report, Form ARS, was filed on Sep 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (bylaw or fiscal year change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Sep 17, 2026 | — |
| S-1 | Registration statement | Sep 8, 2026 | — |
| 424B3 | Prospectus | May 12, 2026 | — |
| 424B3 | Prospectus | May 12, 2026 | — |
| S-1 | Registration statement | May 4, 2026 | — |
| S-1 | Registration statement | May 4, 2026 | — |
| 424B5 | Prospectus supplement | Apr 16, 2026 | — |
| S-8 | Employee stock plan registration | Mar 12, 2026 | — |
| 424B3 | Prospectus | Feb 11, 2026 | — |
| S-1 | Registration statement | Feb 2, 2026 | — |
| S-3/A | Form s-3/a | Dec 30, 2025 | — |
| 424B3 | Prospectus | Nov 10, 2025 | — |
| S-1 | Registration statement | Oct 20, 2025 | — |
| S-1 | Registration statement | Jul 15, 2025 | — |
| S-3 | Shelf registration | Jul 9, 2025 | — |
| 424B3 | Prospectus | May 29, 2025 | — |
| S-1 | Registration statement | May 21, 2025 | — |
| S-1 | Registration statement | Apr 4, 2025 | — |
| S-8 | Employee stock plan registration | Mar 17, 2025 | — |
| POS AM | Filing | Mar 17, 2025 | — |
| 424B5 | Prospectus supplement | Mar 10, 2025 | — |
| S-1 | Registration statement | Jan 31, 2025 | — |
| 424B5 | Prospectus supplement | Jan 7, 2025 | — |
| 424B3 | Prospectus | Jan 6, 2025 | — |
| FWP | Free writing prospectus | Apr 2, 2024 | — |
| S-1/A | Amended registration statement | Mar 29, 2024 | — |
| S-1 | Registration statement | Mar 18, 2024 | — |
| S-8 | Employee stock plan registration | Mar 15, 2024 | — |
| 424B5 | Prospectus supplement | Nov 15, 2023 | — |
| 424B3 | Prospectus | Jul 13, 2023 | — |
| S-1 | Registration statement | Jun 29, 2023 | — |
| 424B3 | Prospectus | May 18, 2023 | — |
| 424B5 | Prospectus supplement | May 17, 2023 | — |
| S-8 | Employee stock plan registration | Mar 15, 2023 | — |
| 424B3 | Prospectus | Sep 23, 2022 | — |
| S-1 | Registration statement | Sep 14, 2022 | — |
| 424B5 | Prospectus supplement | Jul 25, 2022 | — |
| S-3 | Shelf registration | Jul 1, 2022 | — |
| S-8 | Employee stock plan registration | Mar 16, 2022 | — |
| S-8 | Employee stock plan registration | Jul 19, 2021 | — |
| 424B4 | Prospectus | Jun 28, 2021 | — |
| FWP | Free writing prospectus | Jun 11, 2021 | — |
| S-1/A | Amended registration statement | Jun 11, 2021 | — |
| S-1 | Registration statement | May 27, 2021 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Staten Island, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736243
- Former names
- Acurx Pharmaceuticals, LLC (until Jun 23, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.